Startseite >> Blog >> What are the effects of Metformin or can prevent heart disease

What Are the Effects of Metformin or Can Prevent Heart Disease?

 

Metformin (Metformin) has the effect of lowering blood sugar by inhibiting the production of glucose in the liver. It is the first-line drug for the treatment of type 2 diabetes and one of the most commonly prescribed drugs in the world. Hundreds of millions of people around the world are taking metformin.

As an old drug, people's research on metformin has never stopped. Many studies have shown that in addition to its hypoglycemic effect, metformin also has the effect of losing weight. Many preclinical and clinical studies have also observed that metformin has beneficial effects in anti-aging, treatment of cognitive impairment, cancer, and cardiovascular diseases, so metformin is also known as the "magic drug".

Atrial fibrillation (AF) lacks effective drugs, resulting in high morbidity and mortality. This study found that metformin, originally used to treat diabetes, is a preferred repurposed drug for the treatment of AF, and that use of metformin was significantly associated with a lower risk of AF.

Atrial fibrillation is the most common persistent cardiac arrhythmia. The incidence of atrial fibrillation increases with age, reaching 10% in people over 75 years old. Patients with atrial fibrillation will greatly increase the risk of stroke and other diseases, which will affect the overall quality of life and longevity of patients.

 Current drugs for the treatment of AF often have serious potential side effects, so there is a great need for new drugs or therapies for AF, and no new drug for the treatment of AF has been approved for more than a decade.

 The research team created a huge molecular interaction network to screen approved old drugs for new uses. In this study, they analyzed three data sources: protein interaction maps, atrial fibrillation-related gene networks, The drug's molecular or genetic target is then used to screen 2,800 FDA-approved drugs.

 The research team found that metformin can target 30 genes related to atrial fibrillation and directly affect the expression of 8 of them. They also found eight other drug candidates in their analysis, but by reviewing extensive patient data, as well as experiments with iPSC-derived atrial-like cardiomyocytes, they identified metformin as the most promising candidate for AF.

Studies have shown that if we use efficient computational methods, such as artificial intelligence (AI) technology for re-screening, it is possible to shorten the time for drug development by more than ten years.



Verwandte Produkte